Table 1.
Baseline characteristics for the HAD alemtuzumab-treated patients in CARE-MS I and II
| Baseline characteristic | Alemtuzumab-treated HAD patients | |
|---|---|---|
| CARE-MS I (N = 105) | CARE-MS II (N = 103) | |
| Age (years) | 32.1 (8.0) | 32.7 (7.7) |
| Female, n (%) | 69 (66) | 69 (67) |
| EDSS score | 2.0 (0.8) | 2.6 (1.2) |
| Years since initial relapse | 1.7 (1.4) | 4.0 (2.6) |
| Number of relapses in prior 1 year | 2.3 (0.6) | 2.4 (0.8) |
| Number of relapses in prior 2 years | 2.9 (1.0) | 3.4 (1.4) |
| Gd-enhancing lesion count | 5.6 (7.1) | 5.2 (6.2) |
| Patients with Gd-enhancing lesions, n (%) | 105 (100) | 103 (100) |
| T2-hyperintense lesion volume (cm3) | 9.9 (10.1) | 12.1 (12.2) |
| Brain parenchymal fraction | 0.82 (0.02) | 0.82 (0.02) |
| Number of previous DMTs received, n (%) | ||
| 0 | 105 (100) | 0 |
| 1 | – | 69 (67) |
| 2 | – | 26 (25) |
| 3 | – | 5 (5) |
| ≥ 4 | – | 3 (3) |
| Previous DMTs received, n (%) | ||
| IFNB-1a | – | 59 (57) |
| IFNB-1b | – | 32 (31) |
| Glatiramer acetate | – | 42 (41) |
| Natalizumab | – | 7 (7) |
| Immunoglobulin | – | 3 (3) |
| Azathioprine | – | 4 (4) |
Values are mean (SD) unless otherwise noted
Primary HAD definition: ≥ 2 relapses in the year prior to baseline and ≥ 1 Gd-enhancing lesion at baseline
CARE-MS Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, Gd gadolinium, HAD highly active disease, IFNB interferon-β; SD standard deviation